UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $984,000 Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 67.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 43,714 shares of the company’s stock after buying an additional 17,546 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.09% of Enliven Therapeutics worth $984,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Stempoint Capital LP bought a new stake in Enliven Therapeutics in the 4th quarter valued at $2,176,000. Polar Capital Holdings Plc boosted its holdings in Enliven Therapeutics by 267.6% in the 4th quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company’s stock valued at $53,768,000 after purchasing an additional 1,739,668 shares during the period. ProShare Advisors LLC boosted its holdings in Enliven Therapeutics by 29.5% in the 4th quarter. ProShare Advisors LLC now owns 12,229 shares of the company’s stock valued at $275,000 after purchasing an additional 2,788 shares during the period. Patient Square Capital LP boosted its holdings in Enliven Therapeutics by 147.4% in the 4th quarter. Patient Square Capital LP now owns 224,038 shares of the company’s stock valued at $5,041,000 after purchasing an additional 133,466 shares during the period. Finally, Millennium Management LLC boosted its holdings in Enliven Therapeutics by 108.6% in the 4th quarter. Millennium Management LLC now owns 50,804 shares of the company’s stock valued at $1,143,000 after purchasing an additional 26,449 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Jones Trading reduced their price objective on shares of Enliven Therapeutics from $36.00 to $27.00 and set a “buy” rating for the company in a report on Friday, May 16th. HC Wainwright raised their price objective on shares of Enliven Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, May 15th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $37.25.

Enliven Therapeutics Price Performance

Enliven Therapeutics stock opened at $21.70 on Wednesday. The company’s 50 day simple moving average is $18.09 and its 200 day simple moving average is $20.72. Enliven Therapeutics, Inc. has a fifty-two week low of $13.30 and a fifty-two week high of $30.03. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of -11.42 and a beta of 0.79.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.06). As a group, analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Insider Transactions at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 3,250 shares of the business’s stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $21.33, for a total transaction of $69,322.50. Following the transaction, the chief financial officer now directly owns 23,000 shares in the company, valued at approximately $490,590. The trade was a 12.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Samuel Kintz sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $20.05, for a total transaction of $150,375.00. Following the sale, the chief executive officer now owns 965,392 shares of the company’s stock, valued at $19,356,109.60. This trade represents a 0.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 94,444 shares of company stock valued at $1,801,057 over the last 90 days. 25.90% of the stock is owned by corporate insiders.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.